CAMBRIDGE, Mass.– Pi Health, a global health technology and clinical research company, said Wednesday it will collaborate with GSK to deliver end-to-end clinical research services for a Phase 2 oncology clinical trial. The partnership, executed under a Master Clinical Services Outsourcing Agreement, aims to accelerate trial timelines and improve efficiency through Pi Health’s proprietary technology platform.
Pi Health will oversee all aspects of the GSK trial, including site selection, patient enrollment, study conduct, real-time monitoring and regulatory submissions. The company will deploy its Front-end Interoperable Capture System (FICS), an AI-enabled platform designed to unify trial management, enhance compliance, streamline data flow and automate manual processes. According to Pi Health, the system can cut study timelines by up to 50 percent while maintaining audit-ready data quality.
“By applying Pi Health’s technology and international reach to GSK’s global scale and expertise, we believe we can accelerate the development of vital treatments for patients in need of new therapies by making clinical trials faster and more efficient,” said Geoffrey Kim, M.D., CEO and co-founder of Pi Health and former Deputy Director of the FDA’s Oncology Center of Excellence. “This collaboration validates our commitment to fundamentally reimagining how trials should be run. Our technology provides the transparency and efficiency that senior leadership demands while delivering the data quality that regulators require.”
Bobby Reddy, M.D., Chief Operating Officer and co-founder of Pi Health, added: “We are thrilled about what this agreement represents for global drug development. We are optimistic about collaborating with GSK to support its efforts in streamlining clinical trial delivery, with our shared goal of developing medicines more efficiently for patients.”
Zeshaan Rasheed, M.D., Ph.D., Senior Vice President and Head of Oncology Clinical Development at GSK, said Pi Health’s integrated approach and deep industry expertise made the company a strong partner. “By removing inefficiencies that can slow progress in clinical trials, Pi Health is well positioned to help us focus on our main priority: getting innovative medicines to people with cancer as quickly and as safely as possible.”
Founded by physicians, Pi Health has assembled a team of experienced clinicians, principal investigators, and former industry and FDA leaders with extensive drug development and regulatory backgrounds. The company said this multidisciplinary expertise provides unique insight into the challenges and opportunities in clinical research.
